Neuropsychological Evaluation in Intellectual Disability (ENDI)
NCT ID: NCT07047963
Last Updated: 2025-07-02
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
40 participants
OBSERVATIONAL
2025-07-01
2026-11-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
In this study, three types of population will be recruted : normotypic volunteers, patients with Intellectual Disability and patients T21carriers.
This study is separated into 2 phases :
* A the preliminary phase : this phase will be used to evaluate subtest design, ergonomics and understanding of instructions, and to identify any malfunctions. The observations gathered will enable the principal investigator to refine the digital design of the battery in collaboration with the publishing company. In this phase, normotypical volunteers and patients with intellectual disabilities will be recruted to perform ENDI test battery.
* A main phase : this phase will enable to answer to the main objective. in this phase, patients with Trisomy 21 aged between 25 and 65 will be recruted to perform ENDI test battery.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Anxiety, Stress and Sleep Problems in People With Early Onset Dementia
NCT05555381
Interest and Feasibility of the DIGItracking Technique for the Early Diagnosis of COGnitive Disorders
NCT05784623
Sensory Support Care for Elderly Patients Suffering From Alzheimer'S-type Neurodegenerative Disease
NCT01819714
A Cohort Study of Early Onset Neurodegenerative Dementias Prognostic Factors
NCT04254094
Neurodevelopmental Disorder Diagnosis During Adulthood
NCT06691048
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This raises questions about the ageing of this population, all the more so as it is likely to occur earlier, due to reduced neuronal reserve. For example, signs of aging appear 10 years earlier in people with ID, at around age 55. Moreover, this aging process is said to be accelerated Normal cognitive aging in trisomy 21 patients is poorly characterized in the literature; similarly, there is no consensus regarding prodromal signs of Alzheimer's Disease (AD) in T21. However, the presence of the supernumerary chromosome containing the APP (Amyloid Precursor Protein) gene increases the risk of developing AD: 20% of trisomy 21 patients aged 45 and over develop a major neurocognitive disorder (MNCD), and over 50% by the age of 55. T21 is now considered a genetic form of AD, similar to an autosomal dominant form. Identifying AD in this population is therefore a real challenge, especially as AD is identified as the cause of 70% of deaths in trisomy 21 patients.
In cognitive terms, the precursor signs of AD are impairment of memory and temporo-spatial orientation, followed by impairment of praxis, language and visuo-spatial skills. Other authors suggest an early decline in executive functions. More recently, Startin et al. (2019) show that memory and attention tests are more sensitive in detecting prodromal forms. Establishing a diagnosis of neurodegenerative disease in trisomy 21 patients is important for at least 3 reasons. People with intellectual disabilities are often treated with neuroleptics, whose use is not recommended in AD. It also contributes to the adaptation of medical and social care, as ageing disabled people with AD will experience less frequent difficulties, including behavioural changes. According to the Edinburgh Principles, it is important to "ensure that appropriate diagnostic, assessment and intervention resources and services are available to meet the individual needs and promote the healthy ageing of people with intellectual disabilities and cognitive impairment". Finally, at a time when promising pharmacological treatments for AD are emerging for neurotypical subjects, it seems crucial that trisomy 21 patients, who are more at risk of AD, should be diagnosed as early as possible so that they can ultimately benefit from these new therapies. Neuropsychological assessment plays a crucial role in the diagnostic process, as brain imaging and lumbar puncture for AD biomarkers in cerebrospinal fluid are not always feasible.
However, a number of problems remain:
* Neuropsychological assessment is conditioned by the severity of the intellectual disability and the level of literacy/numeracy.
* Few adapted tests are available in French. Tests used in the general population are not transposable, and those based on child assessment batteries are infantilizing.
* Few tests incorporate the evolution of digital technologies, which make it possible to offer more playful interfaces with better temporal control.
* Few tests allow for longitudinal follow-up (no parallel versions, no longitudinal standards), whereas current recommendations call for systematic annual follow-up from the age of 30. In this context, it is essential to develop new cognitive tools integrating digital technologies and innovative approaches, which are indispensable for accurate diagnosis and monitoring of cognitive disorders in trisomy 21 patients. It was with this in mind that the ENDI (Evaluation Neuropsychologique dans la Déficience Intellectuelle) battery was designed. This neuropsychological battery comprises 15 subtests designed to assess language, memory, attention and executive skills. By analyzing changes in trisomy 21 patients performance over time, the neuropsychologist can detect early signs of AD. A pre-test of the ENDI battery is planned to evaluate subtest design, ergonomics and comprehension of instructions, and to identify any malfunctions. The observations gathered will enable the principal investigator to refine the digital design of the battery in collaboration with the publishing company.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
OTHER
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Trisomy 21 patients
Trisomy 21 patients recruted on Main Phase will perform the ENDI tests in order to assess the acceptability of the subtests (individually) and the full neuropsychological battery
ENDI (Neuropsychological Evaluation in Intellectual Disability)
This neuropsychological battery comprises 15 subtests designed to assess language, memory, attention and executive skills. By analyzing changes in Trisomy 21 patients performance over time, the neuropsychologist can detect early signs of Alzheimer's disease.
Patients with Intellectual Disabilities
Patients with Intellectual Disabilities recruted on Preliminary Phase will be will carry out the ENDI tests in order to evaluate subtest design, ergonomics, understanding of instructions and identify any malfunctions. The observations gathered will enable the principal investigator to refine the digital design of the battery in collaboration with the publishing company.
ENDI (Neuropsychological Evaluation in Intellectual Disability)
This neuropsychological battery comprises 15 subtests designed to assess language, memory, attention and executive skills. By analyzing changes in Trisomy 21 patients performance over time, the neuropsychologist can detect early signs of Alzheimer's disease.
Normotypical volunteers
Normotypical volunteers recruted on Preliminary Phase will be will carry out the ENDI tests in order to evaluate subtest design, ergonomics, understanding of instructions and identify any malfunctions. The observations gathered will enable the principal investigator to refine the digital design of the battery in collaboration with the publishing company.
ENDI (Neuropsychological Evaluation in Intellectual Disability)
This neuropsychological battery comprises 15 subtests designed to assess language, memory, attention and executive skills. By analyzing changes in Trisomy 21 patients performance over time, the neuropsychologist can detect early signs of Alzheimer's disease.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
ENDI (Neuropsychological Evaluation in Intellectual Disability)
This neuropsychological battery comprises 15 subtests designed to assess language, memory, attention and executive skills. By analyzing changes in Trisomy 21 patients performance over time, the neuropsychologist can detect early signs of Alzheimer's disease.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Participant who has received full information on the organization of the research and has not objected to his or her participation and to the use of his or her data.
* Legal guardian of the participant, if applicable, who has received full information on the organization of the research and has not objected to participation and use of his/her data.
* Age at inclusion: ≥ 25 and ≤ 65 years
* Notion of intellectual disability in medical records
* Access to the oral language of the participant with an intellectual disability: the subject's speech must be comprehensible to the evaluator and the subject must be able to understand simple statements. It is not possible to use an oral comprehension test (e.g. Token test by Renzi \& Vignolo, 1962), as the norms achieved in healthy subjects would exclude almost all patients with intellectual disabilities, who have more limited language skills.
* Enrolled in or benefiting from a social security scheme.
* Participant having received full information on the organization of the research and not having objected to his or her participation and to the use of his or her data.
* Age at inclusion: ≥ 25 and ≤ 65 years
* Affiliation with a social security scheme or beneficiary of such a scheme
Main phase:
* Participant with T21 who has received full information on the organization of the research and has not objected to participation and use of his/her data
* Legal guardian of the participant with T21, where applicable, who has received full information on the organization of the research and has not objected to his or her participation and the use of his or her data.
* Person with trisomy 21
* Age at inclusion: ≥ 25 and ≤ 65 years
* Access to the oral language of the participant with T21: the subject's speech must be comprehensible to the evaluator and the subject must be able to understand simple statements. It is not possible to use an oral comprehension test (e.g. Token test by Renzi \& Vignolo, 1962), as the norms achieved in healthy subjects would exclude almost all patients with intellectual disabilities, who have more limited language skills.
* Membership of a social security scheme or beneficiary of such a scheme
Exclusion Criteria
* Insufficient command of the French language to complete the tests
* Severe general medical condition or alcoholism (habitual consumption of 3 drinks/day or history of alcohol withdrawal)
* History of stroke, severe head trauma, or cancer
* Change in long-term medication within 8 weeks prior to evaluation
* Refusal to participate by the subject and/or legal representative
* Individuals referred to in Articles L.1121-5 to L.1121-7 of the French Public Health Code:
* Pregnant women, women in labor, or breastfeeding mothers
* Individuals deprived of liberty by judicial or administrative decision
* Individuals undergoing psychiatric treatment under Article L.3213-1 of the French Public Health Code
25 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Central Hospital, Nancy, France
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
COQUELET Amelie
Principal Investigator
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CHRU de Nancy
Vandœuvre-lès-Nancy, Grand Est, France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Hithersay R, Startin CM, Hamburg S, Mok KY, Hardy J, Fisher EMC, Tybulewicz VLJ, Nizetic D, Strydom A. Association of Dementia With Mortality Among Adults With Down Syndrome Older Than 35 Years. JAMA Neurol. 2019 Feb 1;76(2):152-160. doi: 10.1001/jamaneurol.2018.3616.
Coquelet A, Besozzi A, Roussel M, Lemetayer F. Evaluation neuropsychologique des adultes porteurs d'une trisomie 21 en Consultation memoire : quels outils ? Une revue de la litterature. Geriatr Psychol Neuropsychiatr Vieil. 2022 Mar 1;20(1):79-95. doi: 10.1684/pnv.2022.1025. French.
Coppus AW, Fekkes D, Verhoeven WM, Tuinier S, Egger JI, van Duijn CM. Plasma amino acids and neopterin in healthy persons with Down's syndrome. J Neural Transm (Vienna). 2007;114(8):1041-5. doi: 10.1007/s00702-007-0656-1. Epub 2007 Mar 31.
Carmeli E, Imam B, Bachar A, Merrick J. Inflammation and oxidative stress as biomarkers of premature aging in persons with intellectual disability. Res Dev Disabil. 2012 Mar-Apr;33(2):369-75. doi: 10.1016/j.ridd.2011.10.002. Epub 2011 Nov 25.
Burt DB, Aylward EH. Test battery for the diagnosis of dementia in individuals with intellectual disability. Working Group for the Establishment of Criteria for the Diagnosis of Dementia in Individuals with Intellectual Disability. J Intellect Disabil Res. 2000 Apr;44 ( Pt 2):175-80. doi: 10.1046/j.1365-2788.2000.00264.x.
Devenny DA, Zimmerli EJ, Kittler P, Krinsky-McHale SJ. Cued recall in early-stage dementia in adults with Down's syndrome. J Intellect Disabil Res. 2002 Sep;46(Pt 6):472-83. doi: 10.1046/j.1365-2788.2002.00417.x.
Startin CM, Hamburg S, Hithersay R, Al-Janabi T, Mok KY, Hardy J; LonDownS Consortium; Strydom A. Cognitive markers of preclinical and prodromal Alzheimer's disease in Down syndrome. Alzheimers Dement. 2019 Feb;15(2):245-257. doi: 10.1016/j.jalz.2018.08.009. Epub 2018 Nov 28.
Zis P, Strydom A. Clinical aspects and biomarkers of Alzheimer's disease in Down syndrome. Free Radic Biol Med. 2018 Jan;114:3-9. doi: 10.1016/j.freeradbiomed.2017.08.024. Epub 2017 Sep 1.
McCarron M, McCallion P, Reilly E, Dunne P, Carroll R, Mulryan N. A prospective 20-year longitudinal follow-up of dementia in persons with Down syndrome. J Intellect Disabil Res. 2017 Sep;61(9):843-852. doi: 10.1111/jir.12390. Epub 2017 Jun 29.
Lott IT, Head E. Down syndrome and Alzheimer's disease: a link between development and aging. Ment Retard Dev Disabil Res Rev. 2001;7(3):172-8. doi: 10.1002/mrdd.1025.
Lautarescu BA, Holland AJ, Zaman SH. The Early Presentation of Dementia in People with Down Syndrome: a Systematic Review of Longitudinal Studies. Neuropsychol Rev. 2017 Mar;27(1):31-45. doi: 10.1007/s11065-017-9341-9. Epub 2017 Mar 13.
Hartley D, Blumenthal T, Carrillo M, DiPaolo G, Esralew L, Gardiner K, Granholm AC, Iqbal K, Krams M, Lemere C, Lott I, Mobley W, Ness S, Nixon R, Potter H, Reeves R, Sabbagh M, Silverman W, Tycko B, Whitten M, Wisniewski T. Down syndrome and Alzheimer's disease: Common pathways, common goals. Alzheimers Dement. 2015 Jun;11(6):700-9. doi: 10.1016/j.jalz.2014.10.007. Epub 2014 Dec 12.
Godefroy O, Martinaud O, Verny M, Mosca C, Lenoir H, Bretault E, Roussel M. The dysexecutive syndrome of Alzheimer's disease: the GREFEX study. J Alzheimers Dis. 2014;42(4):1203-8. doi: 10.3233/JAD-140585.
Fortea J, Vilaplana E, Carmona-Iragui M, Benejam B, Videla L, Barroeta I, Fernandez S, Altuna M, Pegueroles J, Montal V, Valldeneu S, Gimenez S, Gonzalez-Ortiz S, Munoz L, Estelles T, Illan-Gala I, Belbin O, Camacho V, Wilson LR, Annus T, Osorio RS, Videla S, Lehmann S, Holland AJ, Alcolea D, Clarimon J, Zaman SH, Blesa R, Lleo A. Clinical and biomarker changes of Alzheimer's disease in adults with Down syndrome: a cross-sectional study. Lancet. 2020 Jun 27;395(10242):1988-1997. doi: 10.1016/S0140-6736(20)30689-9.
Rebillat AS, Hiance-Delahaye A, Falquero S, Radice G, Sacco S. The French translation of the dementia screening questionnaire for individuals with intellectual disabilities is a sensitive tool for screening for dementia in people with Down Syndrome. Res Dev Disabil. 2021 Nov;118:104068. doi: 10.1016/j.ridd.2021.104068. Epub 2021 Aug 28.
Dubois B, Touchon J, Portet F, Ousset PJ, Vellas B, Michel B. ["The 5 words": a simple and sensitive test for the diagnosis of Alzheimer's disease]. Presse Med. 2002 Nov 9;31(36):1696-9. French.
Grober E, Buschke H, Crystal H, Bang S, Dresner R. Screening for dementia by memory testing. Neurology. 1988 Jun;38(6):900-3. doi: 10.1212/wnl.38.6.900.
Krikorian R, Bartok J, Gay N. Tower of London procedure: a standard method and developmental data. J Clin Exp Neuropsychol. 1994 Dec;16(6):840-50. doi: 10.1080/01688639408402697.
DE RENZI E, VIGNOLO LA. The token test: A sensitive test to detect receptive disturbances in aphasics. Brain. 1962 Dec;85:665-78. doi: 10.1093/brain/85.4.665. No abstract available.
Rubenstein E, Hartley S, Bishop L. Epidemiology of Dementia and Alzheimer Disease in Individuals With Down Syndrome. JAMA Neurol. 2020 Feb 1;77(2):262-264. doi: 10.1001/jamaneurol.2019.3666.
Ball SL, Holland AJ, Treppner P, Watson PC, Huppert FA. Executive dysfunction and its association with personality and behaviour changes in the development of Alzheimer's disease in adults with Down syndrome and mild to moderate learning disabilities. Br J Clin Psychol. 2008 Mar;47(Pt 1):1-29. doi: 10.1348/014466507X230967.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024- A01565- 42
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.